A 100% tariff on imported drugs just expanded to cover every drugmaker in the country, yet the biotech market's most closely watched fund treated it like a non-event. The reason says everything…
uniQure lost more than a third of its value in a single session after Huntington's data spooked investors, but Wall Street's price target still points to triple-digit upside. Whether that gap represents…
Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains…
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the…
Moderna just posted an 11% surge with zero news behind it, while its longtime mRNA peer BioNTech can barely keep pace with the broader biotech sector. Something broke between these two names,…
XBI and PBE both bet on biotech, but their structures pull in opposite directions when markets turn volatile. Knowing which one fits your risk appetite could mean the difference between riding a…
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally…
Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over the trailing month ending July 1, 2026, a run that would…
Markets are hunting for new leadership as the Big Tech engine sputters, and one Wall Street technician thinks she knows where the baton is being passed. On CNBC’s Closing Bell Overtime, Fairlead…
The Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) is down about 5% year to date while the S&P 500 is up 7%. Over five years, FHLC has returned 15% against about 80%…
If you bought XBI a year ago and held it, you are up roughly 65%. If you bought Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) on the same day, you are…
Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and renewed merger activity pulled capital back into a sector that spent much of the…
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR…
The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: XBI), which tracks the biotech portion of the S&P 500, started…
John Seetoo The bulk of coverage towards the top gaining stock sectors over the past year has focused understandably on technology, which has made huge strides, with semiconductors exceeding +60%. However, the biotech sector…
